Psilocybin-Research.comSearchable psilocybin and psilocin bibliometrics.
CLINICAL TRIAL

Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action

The purpose of this study is to assess brain activity under Psilocybin in a cohort of people with fibromyalgia. This mechanistic (Non-CTIMP) study will utilise a within-subjects design to examine a candidate brain biomarker of increased plasticity under Psilocybin. Up to 25mg of Psilocybin will be administered under standardised conditions on two occasions, separated by four weeks with in-dosing EEG recordings. The primary end-point will take place 8 weeks from the first dosing session after which patients will be remotely monitored monthly for 6 months.

Open source BibTeX RIS

Bibliographic context

Journal
ClinicalTrials.gov
Date
2024-01-18
Source
ClinicalTrials.gov
DOI
Unavailable
PubMed
Unavailable

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers